Despite the tragic disruption brought by the COVID-19 pandemic, IFAPP Academy has undergone a significant transformation which will likely lead us to evolve into a more solid institution and education provider focused on providing services to biomedical professionals working in pharmaceutical medicine and medicines development.
Changes for the rest of 2020 and beyond involve:
- The reformulation of our vision and mission
- The definition of values for our academic and business operations
- The launch of two additional educational programs developed in collaboration with Tufts Center for the Study of Drug Development (Tufts CSDD) and the Medical Affairs Professional Society (MAPS)
- The launch of “Conversations with Academy” as part of our Value-Added Programs (VAPs). “Conversations… will include a series of monthly webinars aimed to discuss hot topics in medicines development and build the foundation for a community of learners. VAPs include several educational tools and are aimed to provide Continuing Professional Development (CPD) services to our students, alumni, Global Fellows, and members of the IFAPP network.
- The expansion of our internal support at the IFAPP Academy Operations Group and the appointment of a Digital Communication Manager and Medical Editor responsible for the VAPs with the collaboration of a new Editorial Board.
- New programs and initiatives to be further offered in 2021 in collaboration with King’s College London and other reputable institutions.
This evolution was possible due to the intense involvement and teamwork shown by our colleagues at the Board in addition to the invaluable support of our IFAPP Academy Operations group and our Advisory Council. IFAPP Academy is emerging as an institution with a global reach and a solid partner to advancing pharmaceutical medicine as a discipline and profession. Let me express my appreciation and acknowledgment for their contributions to the above-mentioned achievements.
